Thais Sielecki Selected Research

CPSI-1306

9/2014	MIF antagonist (CPSI-1306) protects against UVB-induced squamous cell carcinoma.
7/2010	Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thais Sielecki Research Topics

Disease

1	Asthma (Bronchial Asthma) 01/2020
1	Eosinophilia 01/2020
1	Inflammation (Inflammations) 01/2020
1	Carcinogenesis 09/2014
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2014
1	Neoplasms (Cancer) 09/2014
1	Polyuria 07/2010
1	Type 2 Diabetes Mellitus (MODY) 07/2010
1	Ileus 02/2009

Drug/Important Bio-Agent (IBA)

2	Interleukin-6 (Interleukin 6)IBA 01/2020 - 07/2010
2	CPSI-1306IBA 09/2014 - 07/2010
2	CytokinesIBA 09/2014 - 07/2010
2	Macrophage Migration-Inhibitory FactorsIBA 09/2014 - 07/2010
1	AntioxidantsIBA 01/2020
1	LignansIBA 01/2020
1	LGM2605IBA 01/2020
1	secoisolariciresinol diglucosideIBA 01/2020
1	OzoneIBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 01/2020
1	Blood Glucose (Blood Sugar)IBA 07/2010
1	Streptozocin (Streptozotocin)FDA Link 07/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2010
1	semapimodIBA 02/2009
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2009
1	p38 Mitogen-Activated Protein KinasesIBA 02/2009
1	Protein Kinases (Protein Kinase)IBA 02/2009

Therapy/Procedure

1	Oral Administration 07/2010